Is Your Practice Aligned with the Diabetes Canada Guidelines?
QUEST makes it simple to measure your alignment with the latest pharmacotherapy and CKD recommendations
Guidelines Updates at a Glance
Cardiovascular Disease (CVD) & Diabetes
For patients with type 2 diabetes and cardiovascular risk, SGLT2 inhibitors or GLP-1 receptor agonists reduce heart failure, kidney disease progression, stroke, and CV death — even when A1C is at target.
SGLT2i (empagliflozin, canagliflozin, dapagliflozin) → reduce heart failure, kidney progression, CV death.
GLP-1RA (dulaglutide, liraglutide, semaglutide) → reduce stroke and major CV events.
Combination therapy may provide additional benefit, though evidence is emerging.
Chronic Kidney Disease (CKD) & Diabetes
For patients with diabetes and CKD, SGLT2 inhibitors are first-line for renal and CV protection, with GLP-1 receptor agonists added for glucose, weight, or CV risk reduction.
SGLT2i → prioritize in CKD or heart failure; safe to initiate if eGFR ≥20 mL/min/1.73 m².
GLP-1RA → add for further benefit in glycemic or CV risk control.
Combine with ACEi/ARB, statins, and BP control (<130/80 mmHg); monitor electrolytes and kidney function closely.
Kidney Function Testing
Ongoing monitoring is essential, with frequency guided by patient risk.
At diagnosis: eGFR (CKD-EPI 2021) + urine ACR.
Annually: repeat in stable patients.
Abnormal results: repeat eGFR at 3 months, confirm with 2 additional uACR tests.
Every 3–6 months: if CKD, declining eGFR, or persistent albuminuria.
Cutoffs: ACR ≥3.0 mg/mmol = abnormal; eGFR <60 mL/min/1.73 m² signals risk.
New (2025): use KFRE in advanced CKD (G3–G5) to guide referral and risk stratification.
Read the latest Diabetes Canada Guidelines
Turn Guidelines into Action for Your Patients
QUEST delivers a clear, practice-level report highlighting your alignment with the latest CKD and pharmacotherapy recommendations.
Your data, your way.
Choose the data extraction method that fits your clinic. QUEST adapts to you, not the other way around.
Fast and confidential.
Get a clear practice-level snapshot that respects privacy and saves you time.
Practical, patient-first guidance.
Quickly see how guideline updates translate into better care decisions for your patients.
What Your Report Looks Like:
Your report is confidential and tailored to your practice, produced with our partner Amplify Care — a not-for-profit dedicated to helping physicians save time and enhance patient outcomes through smarter technology.
What our Leaders are Saying
-
"Our members see huge opportunity in QUEST. We’ve done our due diligence and know it will add real value for family physicians."
Jess Rogers | CEO, AFHTO
-
“QUEST is an opportunity for family physicians and primary care teams to align their practices with the most recent clinical practice guidelines from Diabetes Canada. The end result is better outcomes for patients and more efficient practices.”
Dave Coughlan | CEO, ICI Medical
-
“When clinicians see their own data, it sparks change — not because someone told them to, but because they see it themselves.”
Ted Alexander | VP, Amplify Care
Powered by Experts in Primary Care, Data, and Education
QUEST is a collaboration between organizations committed to streamlining traditional QI processes to remove barriers to participation.
Get Started with QUEST
Register now to receive your personalized report — or book a call if you still have questions.